Vins Bioproducts Limited

Vins Bioproducts Limited, established on February 17, 1997, is a Hyderabad-based biopharmaceutical company specializing in the production of life-saving immunobiologicals. The company is registered under the Corporate Identification Number (CIN) U24110TG1997PLC026437. Its authorized and paid-up capital stands at ₹200 million (approximately $2.7 million USD). The registered office is located at 806, Essjay House, Road No.3, Banjara Hills, Hyderabad, Telangana, India 500034. Vins Bioproducts Limited is a public unlisted company, classified as a non-government company limited by shares. The company employs between 51 to 200 individuals, reflecting its substantial operational scale. For more information, visit their official website at www.vinsbio.in.

Vins Bioproducts Limited operates state-of-the-art manufacturing facilities in Telangana, India, approximately 40 kilometers from Hyderabad. These facilities are approved by the Pharmaceutical Inspection Co-operation Scheme (PIC/S), ensuring adherence to international manufacturing standards. The company also maintains a 150-acre farm housing over 2,000 equines, which are integral to their immunoglobulin production process. This combination of advanced manufacturing infrastructure and dedicated animal husbandry underscores Vins Bioproducts' commitment to quality and innovation in the biopharmaceutical sector.

The leadership team at Vins Bioproducts Limited is helmed by CEO Khushboo Daga, who has been instrumental in steering the company towards significant milestones. Under her guidance, the company has achieved recognition, including the BW Healthcare 40 Under 40 Award in 2026. The Board of Directors comprises:

• Balkishan Badruka
• Ajit Nair
• Aruna Malani
• Sura Surendranath Reddy
• Shreedass Narayandas Daga
• Shivlal Ramnath Daga
• Siddarth Daga
• Ravindra Reddy Puli

These leaders bring a wealth of experience and strategic vision to the company's operations.

Vins Bioproducts Limited has established a significant presence in regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's products are approved by the World Health Organization (WHO), facilitating access to these markets. Additionally, Vins Bioproducts collaborates with international organizations such as WHO, UNICEF, UNDP, and PAHO, enhancing its global reach and credibility. This strategic positioning underscores the company's commitment to meeting stringent regulatory standards and expanding its footprint in key international markets.

Vins Bioproducts Limited has made significant inroads into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO prequalification status enables it to supply essential immunobiologicals to these regions, addressing critical healthcare needs. By leveraging its expertise and regulatory approvals, Vins Bioproducts contributes to improving healthcare outcomes in underserved areas, demonstrating its commitment to global health.

Vins Bioproducts Limited exhibits a diversified geographic strategy, with exports spanning over 110 countries across Asia, Africa, the Middle East, Europe, Australia, North America, and South America. This extensive reach mitigates concentration risk and positions the company to capitalize on global demand for life-saving immunobiologicals. The strategic direction focuses on expanding market access and strengthening partnerships with international organizations to enhance global health outcomes.

Vins Bioproducts Limited's products are approved by the World Health Organization (WHO), facilitating access to regulated markets. However, specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. This information is crucial for assessing the company's standing in the U.S. market and its compliance with FDA regulations.

Vins Bioproducts Limited's manufacturing facilities are approved by the Pharmaceutical Inspection Co-operation Scheme (PIC/S), ensuring adherence to international Good Manufacturing Practice (GMP) standards. The company's products are also approved by the World Health Organization (WHO), facilitating access to regulated markets. However, specific details regarding EU GMP certificates and European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly available. This information is essential for evaluating the company's compliance with European regulatory standards.

Vins Bioproducts Limited holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO), the national regulatory authority in India. The company's products are approved by the World Health Organization (WHO), facilitating access to regulated markets. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly available. This information is vital for assessing the company's compliance with Indian regulatory requirements and its ability to export products.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Vins Bioproducts Limited. This absence of regulatory actions suggests a strong compliance record. However, the lack of detailed information regarding FDA facility registrations, EU GMP certificates, and CDSCO approvals limits a comprehensive assessment of the company's regulatory standing.

Vins Bioproducts Limited operates in a competitive landscape with several key players in the biopharmaceutical sector, particularly in the production of immunobiologicals. While specific market share data is not publicly available, the company's focus on life-saving antisera and antitoxins positions it as a significant entity in this niche market. The company's collaborations with international organizations such as WHO, UNICEF, UNDP, and PAHO enhance its competitive edge by expanding its global reach and credibility.

Vins Bioproducts Limited's key differentiators include its specialized focus on life-saving immunobiologicals, advanced manufacturing facilities approved by PIC/S, and a 150-acre equine farm integral to its production process. The company's collaborations with international organizations such as WHO, UNICEF, UNDP, and PAHO further distinguish it in the global market. These factors collectively contribute to the company's competitive advantage in the biopharmaceutical industry.

Vins Bioproducts Limited's current strategic direction focuses on the production of life-saving immunobiologicals, including antisera for snake and scorpion bites, antitoxins for tetanus, diphtheria, and gangrene, and rabies immunoglobulins. The company's collaborations with international organizations such as WHO, UNICEF, UNDP, and PAHO indicate a strategic emphasis on global health initiatives. Future outlooks suggest potential expansion into new therapeutic areas and markets, leveraging its manufacturing capabilities and regulatory approvals.

Vins Bioproducts Limited has demonstrated a consistent track record in the production and export of life-saving immunobiologicals, with a total export value of $15.7 million USD across 383 shipments. The company's portfolio is concentrated, with the top five products accounting for 100% of its exports, indicating a focused approach to product development and market penetration. The absence of publicly available records of regulatory actions suggests a reliable and compliant manufacturing process. However, the lack of detailed information regarding FDA facility registrations, EU GMP certificates, and CDSCO approvals limits a comprehensive assessment of the company's regulatory standing.